Table 2. Open in new tab Bivariate and...

	Bivariate Analysis	Multivariable Analysis
Malignancy (solid organ or hematologic)	.001	1.74 (1.28–2.36)	.012	1.89 (1.15–3.12)
Immunosuppression	.094	1.27 (.96–1.68)	.309	.79 (.49–1.25)
Bacteremia by streptococci	.005	.56 (.37–.84)	.049	.64 (.41–.99)
Bacteremia by enterococci	.001	.42 (.24–.73)	.001	.37 (.20–.69)
Fungemia	.029	2.10 (1.10–4.03)	.242	1.52 (.75–3.07)
Persistent bacteremia/candidemia for 96h^a	<.001	2.49 (1.69–3.69)	<.001	2.55 (1.46–3.49)
Spondylodiscitis	.050	1.70 (1.01–2.86)	.039	1.79 (1.03–3.12)
Infective endocarditis	.013	.70 (.52–.93)	.207	.80 (.57–1.13)
Intrabdominal infection	.001	2.61 (1.52–4.48)	.001	2.86 (1.55–5.27)
Source control
Warranted; not performed within 96h	reference	reference	reference	reference
Warranted; performed within 96h	.015	.59 (.39–.89)	.015	.58 (.38–.90)
Not warranted	.030	.68 (.49–.96)	.122	.75 (.52–1.09)
Antimicrobial treatment
Warranted; not appropriate within 48h^a	reference	reference	reference	reference
Warranted; appropriate within 48h	.008	.46 (.27–.79)	.018	.60 (.39–.92)
Not warranted	1.000	.99 (.51–1.94)	.917	1.04 (.51–2.12)

Bivariate Analysis

Multivariable Analysis

OR (95% CI)

aOR (95% CI)

Malignancy (solid organ or hematologic)

.001

1.74 (1.28–2.36)

.012

1.89 (1.15–3.12)

Immunosuppression

.094

1.27 (.96–1.68)

.309

.79 (.49–1.25)

Bacteremia by streptococci

.005

.56 (.37–.84)

.049

.64 (.41–.99)

Bacteremia by enterococci

.001

.42 (.24–.73)

.001

.37 (.20–.69)

Fungemia

.029

2.10 (1.10–4.03)

.242

1.52 (.75–3.07)

Persistent bacteremia/candidemia for 96h^a

<.001

2.49 (1.69–3.69)

<.001

2.55 (1.46–3.49)

Spondylodiscitis

.050

1.70 (1.01–2.86)

.039

1.79 (1.03–3.12)

Infective endocarditis

.013

.70 (.52–.93)

.207

.80 (.57–1.13)

Intrabdominal infection

.001

2.61 (1.52–4.48)

.001

2.86 (1.55–5.27)

Source control

Warranted; not performed within 96h

reference

Warranted; performed within 96h

.015

.59 (.39–.89)

.015

.58 (.38–.90)

Not warranted

.030

.68 (.49–.96)

.122

.75 (.52–1.09)

Antimicrobial treatment

Warranted; not appropriate within 48h^a

reference

Warranted; appropriate within 48h

.008

.46 (.27–.79)

.018

.60 (.39–.92)

Not warranted

1.000

.99 (.51–1.94)

.917

1.04 (.51–2.12)

	Bivariate Analysis	Multivariable Analysis
Malignancy (solid organ or hematologic)	.001	1.74 (1.28–2.36)	.012	1.89 (1.15–3.12)
Immunosuppression	.094	1.27 (.96–1.68)	.309	.79 (.49–1.25)
Bacteremia by streptococci	.005	.56 (.37–.84)	.049	.64 (.41–.99)
Bacteremia by enterococci	.001	.42 (.24–.73)	.001	.37 (.20–.69)
Fungemia	.029	2.10 (1.10–4.03)	.242	1.52 (.75–3.07)
Persistent bacteremia/candidemia for 96h^a	<.001	2.49 (1.69–3.69)	<.001	2.55 (1.46–3.49)
Spondylodiscitis	.050	1.70 (1.01–2.86)	.039	1.79 (1.03–3.12)
Infective endocarditis	.013	.70 (.52–.93)	.207	.80 (.57–1.13)
Intrabdominal infection	.001	2.61 (1.52–4.48)	.001	2.86 (1.55–5.27)
Source control
Warranted; not performed within 96h	reference	reference	reference	reference
Warranted; performed within 96h	.015	.59 (.39–.89)	.015	.58 (.38–.90)
Not warranted	.030	.68 (.49–.96)	.122	.75 (.52–1.09)
Antimicrobial treatment
Warranted; not appropriate within 48h^a	reference	reference	reference	reference
Warranted; appropriate within 48h	.008	.46 (.27–.79)	.018	.60 (.39–.92)
Not warranted	1.000	.99 (.51–1.94)	.917	1.04 (.51–2.12)

Table 2.

Open in new tab

Bivariate and Multivariable Analyses of Predictors of Persistent Fever Among Patients With Suspected Infective Endocarditis

	Bivariate Analysis		Multivariable Analysis
	P	OR (95% CI)	P	aOR (95% CI)
Malignancy (solid organ or hematologic)	.001	1.74 (1.28–2.36)	.012	1.89 (1.15–3.12)
Immunosuppression	.094	1.27 (.96–1.68)	.309	.79 (.49–1.25)
Bacteremia by streptococci	.005	.56 (.37–.84)	.049	.64 (.41–.99)
Bacteremia by enterococci	.001	.42 (.24–.73)	.001	.37 (.20–.69)
Fungemia	.029	2.10 (1.10–4.03)	.242	1.52 (.75–3.07)
Persistent bacteremia/candidemia for 96h^a	<.001	2.49 (1.69–3.69)	<.001	2.55 (1.46–3.49)
Spondylodiscitis	.050	1.70 (1.01–2.86)	.039	1.79 (1.03–3.12)
Infective endocarditis	.013	.70 (.52–.93)	.207	.80 (.57–1.13)
Intrabdominal infection	.001	2.61 (1.52–4.48)	.001	2.86 (1.55–5.27)
Source control
Warranted; not performed within 96h	reference	reference	reference	reference
Warranted; performed within 96h	.015	.59 (.39–.89)	.015	.58 (.38–.90)
Not warranted	.030	.68 (.49–.96)	.122	.75 (.52–1.09)
Antimicrobial treatment
Warranted; not appropriate within 48h^a	reference	reference	reference	reference
Warranted; appropriate within 48h	.008	.46 (.27–.79)	.018	.60 (.39–.92)
Not warranted	1.000	.99 (.51–1.94)	.917	1.04 (.51–2.12)

	Bivariate Analysis		Multivariable Analysis
	P	OR (95% CI)	P	aOR (95% CI)
Malignancy (solid organ or hematologic)	.001	1.74 (1.28–2.36)	.012	1.89 (1.15–3.12)
Immunosuppression	.094	1.27 (.96–1.68)	.309	.79 (.49–1.25)
Bacteremia by streptococci	.005	.56 (.37–.84)	.049	.64 (.41–.99)
Bacteremia by enterococci	.001	.42 (.24–.73)	.001	.37 (.20–.69)
Fungemia	.029	2.10 (1.10–4.03)	.242	1.52 (.75–3.07)
Persistent bacteremia/candidemia for 96h^a	<.001	2.49 (1.69–3.69)	<.001	2.55 (1.46–3.49)
Spondylodiscitis	.050	1.70 (1.01–2.86)	.039	1.79 (1.03–3.12)
Infective endocarditis	.013	.70 (.52–.93)	.207	.80 (.57–1.13)
Intrabdominal infection	.001	2.61 (1.52–4.48)	.001	2.86 (1.55–5.27)
Source control
Warranted; not performed within 96h	reference	reference	reference	reference
Warranted; performed within 96h	.015	.59 (.39–.89)	.015	.58 (.38–.90)
Not warranted	.030	.68 (.49–.96)	.122	.75 (.52–1.09)
Antimicrobial treatment
Warranted; not appropriate within 48h^a	reference	reference	reference	reference
Warranted; appropriate within 48h	.008	.46 (.27–.79)	.018	.60 (.39–.92)
Not warranted	1.000	.99 (.51–1.94)	.917	1.04 (.51–2.12)

Abbreviations: aOR, adjusted odds ratios; CI, confidence interval; OR, odds ratio.

This Feature Is Available To Subscribers Only